Viral hepatitis C is a serious global problem. According to the WHO, about 150-200 million people suffer from hepatitis C, and 350 thousand people die each year from complications. Hepatitis C morbidity and mortality is progressively increasing and, according to experts, will double by 2020. Although the prevalence of chronic viral hepatitis C is lower in children than adults, about 5 million children worldwide have active viral hepatitis C infection. Results and discussion. Viral hepatitis C is an infectious disease caused by the hepatitis C virus, with a hemocontact mechanism of transmission of the pathogen and a primary lesion of the liver and other internal organs. 11 viral hepatitis C genotypes are known. Viral hepatitis C infection in children differs from adults in several aspects. But the data on this issue is ambiguous. As compared to adults, knowledge of hepatitis C virus infection in children is limited. This is because far fewer children are infected with hepatitis C virus, and children are less likely to have symptoms from their hepatitis C virus infection. More than three quarters of the children are symptomless. Minimal nonspecific and brief symptoms are initially found in approximately 15% of children. These symptoms can be in the form of hyperpyrexia, lethargy, anorexia, nausea, vomiting, and abdominal colic. They can present with deep-colored urine, light-colored feces, arthralgia and yellowish discoloration of skin and sclera. In developed countries the children are infected mainly through vertical transmission during deliveries, while in developing countries it is still due to horizontal transmission from adults. Vertical transmission in infants and children can affect 4% to 10% of infants born to viral hepatitis C infected mothers. The risk of vertical transmission escalates when mothers have high viral load and when there is maternal co-infection with human immunodeficiency virus. When the density of maternal viral hepatitis C was 1 million particles per milliliter, the rate of vertical transmission reached 36%. The progression of viral hepatitis C infection to such serious outcomes as cirrhosis and hepatocellular cancer is well studied in adults, but little is known about the long-term outcome of infection in children. It is believed that in children there is a high frequency of spontaneous regression of chronic viral hepatitis C, a slower rate of disease progression than in adults, a predominantly mild asymptomatic course with a slight increase in transaminase level. Indeed, according to a number of investigations, spontaneous remission in children occurs in 25-40% of cases. But we have found and other studies. According to these studies, 60% of the viral hepatitis C RNA-positive children, whom a diagnostic liver biopsy was made, showed chronic hepatitis in 73%, cirrhosis in only one, while seven children (27%) had normal liver biopsies. So, viral hepatitis C infection is frequently not a benign disease during childhood. Conclusions. Thus, studying the literature data, we can conclude that there are number of contradictory data that require further study of viral hepatitis C infection in children.

Keywords: viral hepatitis C, children, course of the disease

Full text: PDF (Ukr) 225K

1. Berezenko VS. Klіnіko-patogenetichnі osoblivostі fіbrogenezu pechіnki pri hronіchnih gepatitah u dіtej ta shljahi jogo medikamentoznoї korekcії: Abstr. Dr. Sci. (Med.). K; 2007. 37 s. [Ukrainian]
2. Denisova MF. Nauchno-prakticheskie prioritety detskoj gepatologii. Suchasna gastroenterologіja. 2009; 6(50): 115-8. [Russian]
3. Moskovskaja IA. Bolezni pecheni u detej. Ed by MJa Studenikin. Tula: Grif i K; 2007. 536 s. [Russian]
4. Sіrchak ES, Petrichko OІ, Іvachevs'kij MM, ta іn. Neіnvazivnі metodi dіagnostiki fіbrozu pechіnki. Ukrainskij zhurnal hirurgii. 2012; 1(16): 76-83. [Ukrainian]
5. Pirogova IJu, Pyshkin SA. Algoritm differencial'noj diagnostiki hronicheskogo gepatita i cirroza pecheni u bol'nyh s hronicheskoj HCV- i HBV-infekciej. Klinicheskie perspektivy gastrojenterologii, gepatologii. 2011; 2: 19-26. [Russian]
6. Rejzis AR. Gepatit C u detej i podrostkov [digital resource]: Medicinskij nauchno-prakticheskij portal. Lechashhij vrach. Moskva. Available from: https://www.lvrach.ru/2003/03/4530166/ [Russian]
7. Nakaz Mіnіsterstva ohoroni zdorov'ja Ukraїni № 729 vіd 18.07.2016. Unіfіkovanij klіnіchnij protokol pervinnoї, vtorinnoї (specіalіzovanoї), tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi dіtjam z vіrusnim gepatitom C. Available from: https://zakon.rada.gov.ua/rada/show/v0729282-16 [Ukrainian]
8. Uchajkin VF, Nisevich NI, Cherednichenko TV. Virusnye gepatity ot A do TTV u detej. M: Novaja volna; 2003. 432 s. [Russian]
9. Car'ova OV. Klіnіko-dіagnostichnі kriterії progresuvannja hronіchnih vіrusnih gepatitіv v ta s u dіtej: Abstr. PhDr. (Med.). K; 2017. 182 s. [Ukrainian]
10. American Association for the Study of Liver Diseases: HCV guidance: Recommendations for testing, managing, and treating hepatitis C [digital resource]. Available from: https://www.hcvguidelines.org/unique-populations/children
11. Baré P. Hepatitis C virus and peripheral blood mononuclear cell reservoirs. World J Hepatol. 2009; 1: 67–71. https://www.ncbi.nlm.nih.gov/pubmed/21160967. https://www.ncbi.nlm.nih.gov/pmc/articles/2999261. https://doi.org/10.4254/wjh.v1.i1.67
12. Bortolotti F, Muratori L, Jara P, Hierro L, Verucchi G, Giacchino R, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr. 2003; 142: 185–90. https://www.ncbi.nlm.nih.gov/pubmed/12584542. https://doi.org/10.1067/mpd.2003.45
13. Bortolotti F, Resti M, Marcellini M, Giacchino R, Verucchi G, Nebbia G, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut. 2005; 54 (6): 852–7. https://www.ncbi.nlm.nih.gov/pubmed/15888796. https://www.ncbi.nlm.nih.gov/pmc/articles/1774540. https://doi.org/10.1136/gut.2004.053744
14. Bortolotti F, Verucchi G, Cammà C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134: 1900–7. https://www.ncbi.nlm.nih.gov/pubmed/18439604. https://doi.org/10.1053/j.gastro.2008.02.082
15. Casiraghi MAntonietta, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, et al.. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology (Baltimore, Md). 2004; 39(1): 90-6. https://www.ncbi.nlm.nih.gov/pubmed/14752827. https://doi.org/10.1002/hep.20030
16. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012; 142: 1293-302. https://www.ncbi.nlm.nih.gov/pubmed/22537436. https://doi.org/10.1053/j.gastro.2012.02.017
17. Abe H, Ochi H, Maekawa T, Ochi H, Hayes CN. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010; 53(3): 439-43. https://www.ncbi.nlm.nih.gov/pubmed/20576307. https://doi.org/10.1016/j.jhep.2010.03.022
18. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53: 1013-21. https://www.ncbi.nlm.nih.gov/pubmed/20850886. https://doi.org/10.1016/j.jhep.2010.05.035
19. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005; 41: 45–51. https://www.ncbi.nlm.nih.gov/pubmed/15937762. https://doi.org/10.1086/430601
20. Li W, Jiang Y, Jin Q, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011; 31(8): 1118-26. https://www.ncbi.nlm.nih.gov/pubmed/21745278. https://doi.org/10.1111/j.1478-3231.2011.02507.x
21. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, et al. Fibrosis Progression in Chronic Hepatitis C: Morphometric Image Analysis in the HALT-C Trial. Hepatology. 2009; 50(6): 1738-49. https://www.ncbi.nlm.nih.gov/pmc/articles/3707633. https://www.ncbi.nlm.nih.gov/pubmed/19824074. https://doi.org/10.1002/hep.23211
22. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-47. https://www.ncbi.nlm.nih.gov/pubmed/20060832. https://doi.org/10.1053/j.gastro.2009.12.056
23. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401. https://www.ncbi.nlm.nih.gov/pubmed/19684573 https://doi.org/10.1038/nature08309
24. Gonzalez-Peralta RP, Langham MR, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. Journal of Pediatric Gastroenterology and Nutrition. 2009; 48(5): 630-5. https://www.ncbi.nlm.nih.gov/pubmed/19412012. https://doi.org/10.1097/MPG.0b013e318170af04
25. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology. 2014; 61(1 Suppl): 45-57. https://www.ncbi.nlm.nih.gov/pubmed/25086286. https://doi.org/10.1016/j.jhep.2014.07.027
26. Guido M, Bortolotti F, Leandro G, Jara P, Hierro L, Larrauri J, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol. 2003; 98: 660–3. https://www.ncbi.nlm.nih.gov/pubmed/12650803. https://doi.org/10.1111/j.1572-0241.2003.07293.x
27. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22. https://www.ncbi.nlm.nih.gov/pubmed/21146242. https://doi.org/10.1016/j.jhep.2010.07.019
28. Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis. 2007; 44(8): 1123-31. https://www.ncbi.nlm.nih.gov/pubmed/17366462. https://doi.org/10.1086/512815
29. Jara P, Hierro L. Treatment of hepatitis C in children. Expert Rev Gastroenterol Hepatol. 2010; 4: 51–61. https://www.ncbi.nlm.nih.gov/pubmed/20136589. https://doi.org/10.1586/egh.09.76
30. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J. 2011; 30: 983–5. https://www.ncbi.nlm.nih.gov/pubmed/21997662. https://doi.org/10.1097/INF.0b013e318236ac37
31. Mast EE, Hwang L-Y, Seto DSY, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. The Journal of Infectious Diseases. 2005; 192(11): 1880-9. https://www.ncbi.nlm.nih.gov/pubmed/16267758. https://doi.org/10.1086/497701
32. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61: 77–87. https://www.ncbi.nlm.nih.gov/pubmed/25069599. https://www.ncbi.nlm.nih.gov/pmc/articles/4303918. https://doi.org/10.1002/hep.27259
33. Pawlowska M, Domagalski K, Pniewska A, Smok B, Halota W, Tretyn A. What's new in hepatitis C virus infections in children? World J Gastroenterol. 2015; 21: 10783–9. https://www.ncbi.nlm.nih.gov/pubmed/26478670. https://www.ncbi.nlm.nih.gov/pmc/articles/4600580. https://doi.org/10.3748/wjg.v21.i38.10783
34. Raziky MS, Hawary M, Koofy N, et al. Hepatitis C virus infection in Egyptian. J Viral Hepat. 2004; 11: 471–6. https://www.ncbi.nlm.nih.gov/pmc/articles/2151778. https://www.ncbi.nlm.nih.gov/pubmed/17464514. https://doi.org/10.1111/j.1365-2893.2004.00535.x
35. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192(11): 1880-9. https://www.ncbi.nlm.nih.gov/pubmed/16267758. https://doi.org/10.1086/497701
36. Esmat G, Hashem M, El-Raziky M, et al. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2012; 32(3): 449-56. https://www.ncbi.nlm.nih.gov/pubmed/22098096. https://doi.org/10.1111/j.1478-3231.2011.02643.x
37. Trepo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol. 2011; 55(1): 38-44. https://doi.org/10.1016/j.jhep.2010.10.018
38. Saleh DA, Shebl FM, El-Kamary SS, Magder LS, Allam A, Abdel-Hamid M, et al. Incidence and risk factors for community-acquired hepatitis C infection from birth to 5 years of age in rural Egyptian children. Trans R Soc Trop Med Hyg. 2010; 104(5): 357–63. https://www.ncbi.nlm.nih.gov/pubmed/20153495. https://www.ncbi.nlm.nih.gov/pmc/articles/3278396. https://doi.org/10.1016/j.trstmh.2010.01.009
39. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20(Suppl 1): S3–S14. https://www.ncbi.nlm.nih.gov/pubmed/17486049. https://doi.org/10.1038/modpathol.3800693
40. Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, et al. The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection. PLoS One. 2011; 6(8): e23218. https://www.ncbi.nlm.nih.gov/pubmed/21858035. https://www.ncbi.nlm.nih.gov/pmc/articles/3157356. https://doi.org/10.1371/journal.pone.0023218
41. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. 2009; 15: 5647–53. https://www.ncbi.nlm.nih.gov/pubmed/19960560. https://www.ncbi.nlm.nih.gov/pmc/articles/2789216. https://doi.org/10.3748/wjg.15.5647
42. World Health Organization. Fact Sheet 2015, No 164. WHO Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection [digital resource]. Available from: https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/